Global HIV Infection Pipeline Analysis

Publish Date:- Oct-2013       No Of Pages (300)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS. The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years.

Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



HIV Infection Drug Development by Clinical Phase:

• Research: 31

• Preclinical: 140

• Phase-I: 53

• Phase-I/II: 18

• Phase-II: 39

• Phase-III: 7

• Preregistration: 2

• Registered: 2

• Marketed: 34


The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS. The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years.

Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



HIV Infection Drug Development by Clinical Phase:

• Research: 31

• Preclinical: 140

• Phase-I: 53

• Phase-I/II: 18

• Phase-II: 39

• Phase-III: 7

• Preregistration: 2

• Registered: 2

• Marketed: 34

1. HIV Infection Drug Market Overview



2. HIV Infection Drug Clinical Development Phase: Research

  2.1 Overview

  2.2 HIV Infection Drug Profiles in Clinical Phases



3. HIV Infection Drug Clinical Development Phase: Preclinical

  3.1 Overview

  3.2 HIV Infection Drug Profiles in Clinical Phase



4. HIV Infection Drug Clinical Development Phase: Phase-I

  4.1 Overview

  4.2 HIV Infection Drug Profiles in Clinical Phase



5. HIV Infection Drug Clinical Development Phase: Phase-I/II

  5.1 Overview

  5.2 HIV Infection Drug Profiles in Clinical Phase



6. HIV Infection Drug Clinical Development Phase: Phase-II

  6.1 Overview

  6.2 HIV Infection Drug Profiles in Clinical Phase



7. HIV Infection Drug Clinical Development Phase: Phase-III

  7.1 Overview

  7.2 HIV Infection Drug Profiles in Clinical Phase



8. HIV Infection Drug Clinical Development Phase: Preregistration

  8.1 Overview

  8.2 HIV Infection Drug Profiles in Clinical Phase



9. HIV Infection Drug Clinical Development Phase: Registered

  9.1 Overview

  9.2 HIV Infection Drug Profiles in Clinical Phase



10. Marketed Drugs

  10.1 Overview

  10.2 Marketed Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC code

• Designated Brand Name & Orphan Designation